Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.56 |
| ▸ | LAP3 | P28838 | 3/20 | 0.56 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.50 |
| ▸ | LTA4H | P09960 | 1/20 | 0.50 |
| ▸ | MME | P08473 | 4/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Leu-Leu SCHEMBL235249 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL11140120 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL29401942 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL18774992 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL6044006 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL13737576 | 1.00 | ALDH1A1 (0.60) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL30771444 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| Leu-Leu SCHEMBL29400696 | 0.98 | ALDH1A1 (0.58) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| SCHEMBL2722888 | 0.96 | ALDH1A1 (0.56) | ALDH1A1MAPTSLC7A5MEN1LMNA | |
| SCHEMBL1019805 | 0.96 | ALDH1A1 (0.56) | ALDH1A1MAPTSLC7A5MEN1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 561 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026087804-A1 | METHOD FOR PRODUCING SELF-ASSEMBLING DIPEPTIDES | FERTINAGRO BIOTECH, S.L. (ES) | 2026-04-30 | — | — | WO | claimed |
| EP-4731259-A1 | A NANOFORMULATION FOR THERAPEUTIC USE | Council of Scientific and Industrial Research (IN) | 2026-04-29 | — | — | EP | claimed |
| US-20260085094-A1 | STAPLED PEPTIDE AND USE THEREOF | JIANGSU DEYUAN PHARMACEUTICAL CO LTD (CN) | 2026-03-26 | — | — | US | claimed |
| US-20260060913-A1 | BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS | L'OREAL (FR) | 2026-03-05 | — | — | US | claimed |
| EP-4695413-A1 | PHOSPHONOALANINE OLIGOPEPTIDES AND METHODS OF MAKING AND USE THEREOF | Ohio State Innovation Foundation (US) | 2026-02-18 | — | — | EP | claimed |
| EP-4659591-A1 | TASTE-ENHANCING COMPOSITION, METHOD FOR PRODUCING SAME, FOOD PRODUCT, AND METHOD FOR ENHANCING TASTE OF FOOD PRODUCT | House Foods Group Inc. (JP) | 2025-12-10 | — | — | EP | claimed |
| US-20250281564-A1 | DYSREGULATION OF NEUROPROTEASOMES BY APOE ISOFORMS DRIVES ENDOGENOUS TAU AGGREGATION | UNIV COLUMBIA (US) | 2025-09-11 | — | — | US | claimed |
| EP-4597111-A1 | USE OF METABOLIC MARKER FOR DIAGNOSIS OF LUNG CANCER STAGING AND KIT | Harbin Metanotitia Inc. (CN) | 2025-08-06 | — | — | EP | claimed |
| WO-2025124536-A1 | CHEMOKINE RECEPTOR 8 ANTAGONISTIC POLYPEPTIDE COMPOUND, COMPOSITION, KIT, AND USE | 江苏康缘药业股份有限公司 | 2025-06-19 | — | — | WO | claimed |
| EP-4566632-A1 | MSLN ANTIBODY-DRUG CONJUGATE | Nona Biosciences (Suzhou) Co., Ltd. (CN) | 2025-06-11 | — | — | EP | claimed |
| US-20150132440-A1 | DIPEPTIDE AND TRIPEPTIDE COMPOSITIONS AND USES | JHO INTELLECTUAL PROPERTY HOLDINGS, LLC | 2015-05-14 | — | — | US | claimed |
| EP-0910624-B1 | PROCESS FOR PRODUCING AND MULTIPLYING LYMPHOCYTES | ALBERT WINFRIED DR (DE) | 2004-09-22 | — | — | EP | claimed |
| US-6576466-B2 | Activation; separation | Winfried, Albert (DE) | 2003-06-10 | — | — | US | claimed |
| US-5863937-A | PEPTIDE CONJUGATED COMPOUND AS FUNGICIDES, BACTERICIDES, MICROBIOCIDES TREATING CANDIDA ALBICANS INFECTION | BTG INTERNATIONAL LIMITED (GB) | 1999-01-26 | — | — | US | claimed |
| EP-0722456-A1 | ANTIFUNGAL COMPOSITIONS | BTG INTERNATIONAL LIMITED (GB) | 1996-07-24 | — | — | EP | claimed |
| WO-1995009867-A1 | ANTIFUNGAL COMPOSITIONS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1995-04-13 | — | — | WO | claimed |
| EP-0460065-B1 | A PROCESS FOR THE GENERATION OF PROLIFERATING CD4 LYMPHOCYTES | TERUMO CORP (JP) | 1994-08-31 | — | — | EP | claimed |
| EP-0286171-B1 | DIPEPTIDASE, ITS ISOLATION FROM LACTIC ACID BACTERIA, ANTIBODIES AGAINST THE DIPEPTIDASE, THE USE OF THE DIPEPTIDASE AND OF THE ANTIBODIES AGAINST IT | CAMPINA MELKUNIE B.V. (NL) | 1993-03-31 | — | — | EP | claimed |
| US-4888284-A | EXTRACTION USING ION EXCHANGE COLUMN CHROMATOGRAPHY | RIJKSUNIVERSITEIT TE GRONINGEN (NL) | 1989-12-19 | — | — | US | claimed |
| EP-0286171-A1 | Dipeptidase, its isolation from lactic acid bacteria, antibodies against the dipeptidase, the use of the dipeptidase and of the antibodies against it | CAMPINA MELKUNIE B.V. (NL) | 1988-10-12 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250281564-A1 | DYSREGULATION OF NEUROPROTEASOMES BY APOE ISOFORMS DRIVES ENDOGENOUS TAU AGGREGATION | MAPT, PSEN1, PSEN2 | ALDH1A1 4563/4885MAPT 1/4885SLC7A5 4304/4885 |
| US-20260060913-A1 | BIOACTIVE WALNUT PEPTIDES FOR TREATING HAIR LOSS | TYR, CUTA, ARGLU1 | ALDH1A1 4486/4885MAPT 2012/4885SLC7A5 3499/4885 |
| US-20260085094-A1 | STAPLED PEPTIDE AND USE THEREOF | VIP, ARGLU1, NGLY1 | ALDH1A1 4417/4885MAPT 3284/4885SLC7A5 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.